CorMedix, Inc. (NYSE: CRMD) is a commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix’s first commercial product in Europe is Neutrolin, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in the tunneled, cuffed, central venous catheters used for vascular access in hemodialysis, oncology and critical care patients and patients receiving total parenteral nutrition, IV hydration and/or IV medications. For more information, visit the company’s website at www.cormedix.com.